{"id":1616,"date":"2026-07-17T15:00:00","date_gmt":"2026-07-17T15:00:00","guid":{"rendered":"https:\/\/lotilabs.com\/resources\/?p=1616"},"modified":"2026-09-01T16:09:40","modified_gmt":"2026-09-01T16:09:40","slug":"pemvidutide-research-profile-dual-glp-1-glucagon-agonist-mechanisms-in-metabolic-liver-models","status":"publish","type":"post","link":"https:\/\/lotilabs.com\/resources\/pemvidutide-research-profile-dual-glp-1-glucagon-agonist-mechanisms-in-metabolic-liver-models\/","title":{"rendered":"Pemvidutide Research Profile: Dual GLP-1\/Glucagon Agonist Mechanisms in Metabolic &#038; Liver Models"},"content":{"rendered":"<div class=\"ez-toc-v2_0_83 counter-hierarchy ez-toc-counter ez-toc-light-blue ez-toc-container-direction\" id=\"ez-toc-container\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<p><span class=\"ez-toc-title-toggle\"><a aria-label=\"Toggle Table of Content\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" href=\"#\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg class=\"list-377408\" fill=\"none\" height=\"20px\" style=\"fill: #999;color:#999\" viewbox=\"0 0 24 24\" width=\"20px\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg baseprofile=\"tiny\" class=\"arrow-unsorted-368013\" height=\"10px\" style=\"fill: #999;color:#999\" version=\"1.2\" viewbox=\"0 0 24 24\" width=\"10px\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"><\/path><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav>\n<ul class=\"ez-toc-list ez-toc-list-level-1\">\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/lotilabs.com\/resources\/pemvidutide-research-profile-dual-glp-1-glucagon-agonist-mechanisms-in-metabolic-liver-models\/#Pemvidutide_A_Dual_Agonist_with_a_Liver-Targeting_Profile\">Pemvidutide: A Dual Agonist with a Liver-Targeting Profile<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/lotilabs.com\/resources\/pemvidutide-research-profile-dual-glp-1-glucagon-agonist-mechanisms-in-metabolic-liver-models\/#The_Glucagon_Paradox_Why_Activate_a_%E2%80%9CCounterregulatory%E2%80%9D_Hormone_Receptor\">The Glucagon Paradox: Why Activate a \u201cCounterregulatory\u201d Hormone Receptor?<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/lotilabs.com\/resources\/pemvidutide-research-profile-dual-glp-1-glucagon-agonist-mechanisms-in-metabolic-liver-models\/#Mechanism_of_Action_at_the_Receptor_Level\">Mechanism of Action at the Receptor Level<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/lotilabs.com\/resources\/pemvidutide-research-profile-dual-glp-1-glucagon-agonist-mechanisms-in-metabolic-liver-models\/#Pemvidutide_vs_Survodutide_vs_Retatrutide_Differentiating_Dual_and_Triple_Agonists\">Pemvidutide vs. Survodutide vs. Retatrutide: Differentiating Dual and Triple Agonists<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/lotilabs.com\/resources\/pemvidutide-research-profile-dual-glp-1-glucagon-agonist-mechanisms-in-metabolic-liver-models\/#Open_Research_Questions\">Open Research Questions<\/a><\/li>\n<\/ul>\n<\/nav>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Pemvidutide_A_Dual_Agonist_with_a_Liver-Targeting_Profile\"><\/span><span class=\"ez-toc-section\" id=\"Pemvidutide_A_Dual_Agonist_with_a_Liver-Targeting_Profile\"><\/span>Pemvidutide: A Dual Agonist with a Liver-Targeting Profile<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The metabolic peptide landscape has been dominated by GLP-1 receptor agonists and, more recently, dual GIP\/GLP-1 agonists like tirzepatide. Pemvidutide takes a different path. Developed by Altimmune, it is a dual GLP-1\/glucagon receptor agonist \u2014 a peptide that simultaneously activates two receptors with opposing reputations in metabolic research. The combination produces a metabolic profile distinct from either mechanism alone.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"The_Glucagon_Paradox_Why_Activate_a_%E2%80%9CCounterregulatory%E2%80%9D_Hormone_Receptor\"><\/span><span class=\"ez-toc-section\" id=\"The_Glucagon_Paradox_Why_Activate_a_%E2%80%9CCounterregulatory%E2%80%9D_Hormone_Receptor\"><\/span>The Glucagon Paradox: Why Activate a \u201cCounterregulatory\u201d Hormone Receptor?<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Glucagon has been framed as insulin\u2019s antagonist for decades \u2014 the hormone that raises blood glucose during fasting. So why design a peptide that activates its receptor alongside GLP-1? <\/p>\n<p>Glucagon receptor activation in hepatocytes stimulates fatty acid oxidation, ketogenesis, and amino acid catabolism. <\/p>\n<p>The risk, of course, is hyperglycemia. Glucagon raises blood glucose. <\/p>\n<h2><span class=\"ez-toc-section\" id=\"Mechanism_of_Action_at_the_Receptor_Level\"><\/span><span class=\"ez-toc-section\" id=\"Mechanism_of_Action_at_the_Receptor_Level\"><\/span>Mechanism of Action at the Receptor Level<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Pemvidutide is a 30-amino-acid peptide engineered for balanced potency at both the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR). Its sequence incorporates structural elements from both native GLP-1 and glucagon, with modifications to optimize receptor affinity ratios and extend half-life through albumin binding.<\/p>\n<p>The Phase 2 MOMENTUM trial evaluated pemvidutide in adults with obesity over 48 weeks. <\/p>\n<p>This liver-targeting profile led Altimmune to pursue MASH as a primary indication. The Phase 2b IMPACT trial specifically enrolled participants with biopsy-confirmed MASH and fibrosis stages F1\u2013F3. <\/p>\n<p>Safety signals were consistent with the GLP-1 agonist class: nausea, vomiting, and decreased appetite were most common, generally mild, and diminished with continued exposure. <\/p>\n<h2><span class=\"ez-toc-section\" id=\"Pemvidutide_vs_Survodutide_vs_Retatrutide_Differentiating_Dual_and_Triple_Agonists\"><\/span><span class=\"ez-toc-section\" id=\"Pemvidutide_vs_Survodutide_vs_Retatrutide_Differentiating_Dual_and_Triple_Agonists\"><\/span>Pemvidutide vs. Survodutide vs. Retatrutide: Differentiating Dual and Triple Agonists<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The competitive landscape for multi-agonist metabolic peptides is crowded. Survodutide (Boehringer Ingelheim) is also a GLP-1\/glucagon dual agonist, while retatrutide (Eli Lilly) adds a third target \u2014 the GIP receptor \u2014 making it a triple agonist. How does pemvidutide differentiate?<\/p>\n<p>The key distinction appears to be hepatic specificity. Pemvidutide\u2019s glucagon:GLP-1 potency ratio is calibrated to maximize liver fat mobilization. <\/p>\n<p>For researchers studying MASH biology, pemvidutide offers a tool compound with a mechanistically clear hepatic action \u2014 glucagon receptor-driven fat oxidation in the liver, counterbalanced by GLP-1-mediated glycemic control. <\/p>\n<h2><span class=\"ez-toc-section\" id=\"Open_Research_Questions\"><\/span><span class=\"ez-toc-section\" id=\"Open_Research_Questions\"><\/span>Open Research Questions<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p> These are the questions driving pemvidutide research forward into 2026 and beyond.<\/p>\n<p><em>Disclaimer: This content is intended for research purposes only and is not meant to constitute medical advice.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Table of Contents Toggle Pemvidutide: A Dual Agonist with a Liver-Targeting Profile The Glucagon Paradox: Why Activate a \u201cCounterregulatory\u201d Hormone Receptor? Mechanism of Action at the Receptor Level Pemvidutide vs. Survodutide vs. Retatrutide: Differentiating Dual and Triple Agonists Open Research Questions Pemvidutide: A Dual Agonist with a Liver-Targeting Profile The metabolic peptide landscape has been [&#8230;]\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-1616","post","type-post","status-publish","format-standard","hentry","category-peptides"],"_links":{"self":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/1616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/comments?post=1616"}],"version-history":[{"count":0,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/1616\/revisions"}],"wp:attachment":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media?parent=1616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/categories?post=1616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/tags?post=1616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}